Replies to post #28518 on Radient Pharmaceuticals Corporation fka RXPC

[dcspka]

IMO, the Radient merger will be creative and multi-faceted.

Initially it primarily involves Provista/GCDx. However, from the get-go they will be cutting major partnerships to alleviate the test expansion/ad program costs. Lympro will be in the mix as a spin-off, so will CIT. Enter SRL, UBI, Uni-Pharma, etc.